Right sizing funding for Alzheimers disease 英文参考文献.docVIP

Golde et al. Alzheimer’s Research Therapy 2011,3:17 /content/3/3/17 EDITORIAL Right sizing funding for Alzheimer’s disease Todd E Golde* , Bruce T Lamb and Douglas Galasko 1 2 3 Finding novel, e? ective, Alzheimer’s disease (AD) thera- disease-modifying therapeutics f is question peutics has emerged as one of the major unmet medical needs to be asked in the context of the question: “What needs in most developed nations [1,2]. AD is quite factors were enabling in the development of novel anti- unique among highly prevalent diseases within these HIV therapies?” Although there are certainly many nations in that, despite tremendous advances in under- germane medical and scienti? c issues, one critical aspect standing certain aspects of AD pathogenesis, there are no may simply be that the funding for HIV/AIDs research, at proven disease-modifying therapies and only minimally least in the United States, appears to have been su? cient, e? ective symptomatic therapies. ough many other and therefore in retrospect “right sized”, to enable not only prevalent diseases still cause tremendous morbidity and basic understanding of the disease-causing entity and the mortality, for many of them scienti? c and medical disease it causes but also to translate that enhanced advances have led to novel therapies that alter disease understanding into novel and e? ective therapeutics. course, reduce mortality, or at least signi? cantly relieve symptoms for some period of time. Typically, these therapies are not panaceas, or true cures, but nevertheless signi? cant therapeutic inroads have been made. If one assumes that funding for HIV/AIDS was right sized to enable translation of basic discoveries to success- ful therapies,